BackApellis Pharmaceuticals Overview
Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Target Price

Where could APLS trade next? Consensus target price: $62.

Get informed when a big investor buys or sells

+ Follow

Share Price

$41.03

Average Target Price

$62.0051.1% upside

2 analysts in the last 4 months

High: $83 | Low: $41

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-28NeedhamJoseph Stringer$83102.3% upsideOpen
2026-04-17Wells Fargo$410.1% downsideOpen
2026-01-27Barclays$2441.5% downsideOpen
2026-01-20Wells Fargo$2636.6% downsideOpen
2026-01-13Cantor Fitzgerald$3514.7% downsideOpen
2026-01-12Goldman Sachs$1953.7% downsideOpen
2025-12-19Stifel Nicolaus$4817% upsideOpen
2025-11-03Mizuho SecuritiesGraig Suvannavejh$1953.7% downsideOpen
2025-10-31Robert W. Baird$5226.7% upsideOpen
2025-10-31H.C. Wainwright$459.7% upsideOpen
2025-10-29Mizuho Securities$2441.5% downsideOpen
2025-10-15Wells Fargo$3222% downsideOpen
2025-09-26Goldman Sachs$1856.1% downsideOpen
2025-07-30Scotiabank$2246.4% downsideOpen
2024-11-06H.C. WainwrightDouglas Tsao$5738.9% upsideOpen
2024-09-23Robert W. BairdColleen Kusy$92124.2% upsideOpen
2024-09-20Stifel NicolausAnnabel Samimy$84104.7% upsideOpen
2024-09-20Mizuho SecuritiesGraig Suvannavejh$394.9% downsideOpen
2024-09-16Mizuho SecuritiesGraig Suvannavejh$422.4% upsideOpen
2024-08-09Robert W. BairdColleen Kusy$96134% upsideOpen
2024-08-08JefferiesAkash Tewari$8299.9% upsideOpen
2024-08-02H.C. WainwrightDouglas Tsao$83102.3% upsideOpen
2024-07-26Robert W. BairdColleen Kusy$86109.6% upsideOpen
2024-07-01Mizuho SecuritiesGraig Suvannavejh$4919.4% upsideOpen
2024-05-23Wells FargoDerek Archila$4817% upsideOpen
2024-02-05JefferiesAkash Tewari$8095% upsideOpen
2023-01-02Wells FargoDerek Archila$5841.4% upsideOpen
2022-11-15J.P. Morgan$7992.5% upsideOpen
2022-09-12Wedbush$6763.3% upsideOpen
2022-09-08Stifel Nicolaus$6558.4% upsideOpen
2022-08-18Oppenheimer$7890.1% upsideOpen
2022-08-09Credit Suisse$5226.7% upsideOpen
2022-08-09Goldman Sachs$102148.6% upsideOpen
2022-08-09Raymond James$113175.4% upsideOpen
2022-07-20Citigroup$86109.6% upsideOpen
2022-06-23Stifel NicolausAnnabel Samimy$6046.2% upsideOpen
2022-05-24Goldman Sachs$84104.7% upsideOpen
2022-05-05Credit Suisse$447.2% upsideOpen
2022-05-05Raymond James$102148.6% upsideOpen
2021-11-09WedbushLaura Chico$2831.8% downsideOpen
2021-11-09BMO CapitalMatthew Luchini$6968.2% upsideOpen
2021-10-01Cantor FitzgeraldAlethia Young$7480.4% upsideOpen
2021-10-01JefferiesChris Howerton$7480.4% upsideOpen
2021-09-10Credit SuisseTiago Fauth$387.4% downsideOpen
2021-07-01Cowen & Co.Phil Nadeau$7070.6% upsideOpen

Apellis Pharmaceuticals (APLS) FAQ

The latest target price for APLS is $62. Investors often review this figure alongside Apellis Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Apellis Pharmaceuticals trades near $41.03 while the consensus target sits at $62 (51.1% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting APLS's target price ($62), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Apellis Pharmaceuticals's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.